This study is for people with Giant Cell Arteritis (GCA), which affects blood vessels and can cause headaches and jaw pain. It compares two options for stopping or reducing a treatment called Tocilizumab (TCZ) in patients who have been stable for a year. Participants should not have used steroids like prednisone for three months before joining.
Study Details:
- Length: The study lasts about 30 months total, starting with a screening phase up to 42 days.
- Visits Needed: Regular clinic visits every two months for the first 18 months, and then every three months until month 30.
- Risks and Benefits: The main goal is to see if it's safe and effective to reduce or stop TCZ. There are blood tests and health exams involved, but no details on compensation are provided.
People interested must be willing to sign consent forms and follow the study rules. They should not have other autoimmune diseases, recent infections, or be planning pregnancy while participating.
How understandable was the trial content above?
Hard to understand
Easy to understand